Results 181 to 190 of about 8,834,434 (252)

National consensus statement on opioid agonist treatment in custodial settings. [PDF]

Med J Aust
Chan J, Cook J, Curtis M, Dunlop AJ, Morrison E, Nielsen S, Winter RJ, Naren T.   +7 more
europepmc   +1 more source

Peripheral non‐invasive focused ultrasound alleviates constipation by reducing gastrointestinal inflammation

Experimental Physiology, EarlyView.
Abstract Constipation affects approximately 20% of the US population, with diverse treatment options available due to the unclear onset and causes of the condition. Recently, focused ultrasound (FUS) has been proposed as a novel, non‐invasive peripheral neuromodulatory treatment that may reduce this inflammation.
Dia Shah, Kainat Akhtar, Dev Dwivedi, Amal Siddiqui, Griffin Haggas, Nicole Forman, Tatiana Gervase, Yifan Kao, John Chen, Julia Brzac, Eric Molho, Damian Shin   +11 more
wiley   +1 more source

Persisting high rates of mental health disorders in patients in opioid agonist treatment-Results from a 6-year longitudinal study. [PDF]

Am J Addict
Soyka M, Koller G, Hans-Ulrich W, Bühringer G.   +3 more
europepmc   +1 more source

Potential health benefits of cold‐water immersion: the central role of PGC‐1α

The Journal of Physiology, EarlyView.
Abstract figure legend Cold‐water immersion (CWI) elicits autonomic, somato‐motoric (shivering thermogenesis), endocrine and metabolic, sensory transduction, and local biophysical effects that may converge on the transcriptional co‐activator PGC‐1α (centre).
Erich Hohenauer, Wafa Douzi, Johannes Burtscher   +2 more
wiley   +1 more source

Treatment satisfaction among patients in opioid agonist treatment in Norway: A multicenter cohort study. [PDF]

Nordisk Alkohol Nark
Nesse L, Clausen T.
europepmc   +1 more source

Update on Sedation for Upper Gastrointestinal Endoscopy in Japan: Current Evidence on Remimazolam

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Sedation is an essential component of upper gastrointestinal endoscopy because it reduces patient discomfort and anxiety while improving patient acceptance and procedural quality. In Japan, benzodiazepines such as midazolam and opioid analgesics have long been widely used in routine clinical practice; however, many of these agents historically
Ryoji Ichijima, Masahiro Toyama, Taiki Shishido, Yuki Koyo, Takehiro Yoshii, Reona Kawamura, Tsubasa Ishikawa, Yasuhiko Mizuguchi, Naoya Toyoshima, Hiroyuki Takamaru, Masayoshi Yamada, Masau Sekiguchi, Seiichiro Abe, Yutaka Saito   +13 more
wiley   +1 more source

A feasibility study of a co-designed intervention to manage benzodiazepine dependence and high-risk use in those receiving opioid agonist treatment. [PDF]

Pilot Feasibility Stud
Matheson C, Berry K, Kilonzo M, Galea-Singer S, Hill D, Ritchie T, Schofield J, Stewart D, Turner M, MacLennan G.   +9 more
europepmc   +1 more source

Haemodynamic and Respiratory Effects of Dexmedetomidine as an Adjuvant to Oxycodone Patient‐Controlled Analgesia After Lumbar Spinal Fusion: A Post Hoc Analysis of the DoseRespDex Randomised Controlled Trial

Acta Anaesthesiologica Scandinavica, Volume 71, Issue 1, January 2027.
ABSTRACT Purpose Dexmedetomidine has been studied as an adjunct to opioid patient‐controlled analgesia (PCA) because of its opioid‐sparing properties and limited respiratory depression. However, potential dose‐dependent haemodynamic effects should be considered, and data on dexmedetomidine administered via PCA remain limited.
Sanna Mäkelä, Teijo I. Saari, Eliisa Löyttyniemi, Riku Aantaa, Antti Liukas, Panu Uusalo   +5 more
wiley   +1 more source

The potential use of digital technologies to enhance opioid agonist treatment in rural and remote communities of British Columbia, Canada. [PDF]

Harm Reduct J
Jayathilake A, Hodgson K, Mansoor M, Markel K, Bardwell G.   +4 more
europepmc   +1 more source

Characterization of the Lysophosphatidic Acid Receptor 5 Antagonist RLPA‐76 as a Novel Analgesic in Male Rats and Mice

Pharmacology Research &Perspectives, Volume 14, Issue 6, December 2026.
ABSTRACT Clinically used analgesics such as gabapentinoids and opioids have limited efficacy and adverse effects like abuse liability, and there is a dire need for novel analgesics with improved safety profiles. Since lysophosphatidic acid can induce neuropathic pain in rodents, LPA receptor antagonists have been investigated as potential analgesics ...
Kristen L. Woodhouse, Maowei Wang, Sai Ganesh Balaji Venkata Anupindi, Olatunbosun Adeoke, Dehui Zhang, Yanan Zhang, Jun‐Xu Li   +6 more
wiley   +1 more source